- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MODUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.08. | Modus Therapeutics Holding AB: Modus Therapeutics publishes interim report for Q2 2026 | 168 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 August 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes its interim report for the second quarter of 2026. The report is available on the company's... ► Artikel lesen | |
| 28.05. | Modus Therapeutics Holding AB: Annual General Meeting in Modus Therapeutics Holding AB (publ) | 189 | GlobeNewswire (Europe) | Modus Therapeutics' Annual General Meeting on 28 May 2026 resolved in accordance with the following:
That no dividend would be paid.To discharge the board members and the managing director from liability... ► Artikel lesen | |
| 26.05. | Modus Therapeutics Holding AB: Modus Therapeutics publishes interim report for Q1 2026 | 193 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 May 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes its interim report for the first quarter of 2026. The report is available on the company's website... ► Artikel lesen | |
| 25.02. | Modus Therapeutics Holding AB: Modus Therapeutics publishes year-end report for 2025 | 815 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 25 February 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes year-end report for 2025. The report is available on the company's website (www.modustx.com)... ► Artikel lesen | |
| 10.12.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia | 338 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a... ► Artikel lesen | |
| 26.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the third quarter 2025 | 546 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 November 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the third quarter of 2025. The report is available on the company's... ► Artikel lesen | |
| 04.11.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia | 336 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate... ► Artikel lesen | |
| 03.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia | 361 | GlobeNewswire (Europe) | Stockholm, Sweden - November 3, 2025- Modus Therapeutics Holding AB (publ) ("Modus" or the "Company") announces that the competent authorities in Italy have approved the Company's dose selection for... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,735 | +1,17 % | NanoRepro-Aktie: Ist das der beste Nano Cap? | Die NanoRepro AG möchte eine breit aufgestellte Consumer-Health-Plattform entwickeln. Die Aktie ist nach ihren Höhenflug zur Jahresmitte wieder deutlich zurückgekommen. Wie geht es jetzt weiter? Ambitionierte... ► Artikel lesen | |
| MARINOMED BIOTECH | 4,200 | 0,00 % | Marinomed: Rating und Kursziel ausgesetzt | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC befindet sich die Marinomed Biotech AG seit dem 23. Juli in einem Sanierungsverfahren ohne Eigenverwaltung, nachdem Unither... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,142 | 0,00 % | Replenish Nutrients: SRC's Proposed $15M Strategic Investment Supports a 5x Step-Up in Owned Capacity | Company: Replenish NutrientsListings: CSE Canada, Frankfurt and US OTCTickers: ERTH / VVIVF / WIMNMarket cap at time of publication: $38 MCADStock price at time... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 3,210 | +0,31 % | Sana Biotechnology: Zwei Schlüsselprogramme nähern sich klinischen Studien | ||
| NOVABRIDGE BIOSCIENCES | 1,390 | -0,71 % | NovaBridge Biosciences: NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director | Martin Dewhurst appointed as independent director and member of the Audit and Compensation CommitteesVeteran healthcare executive brings more than 30 years of leadership, governance, and strategic... ► Artikel lesen | |
| GENEURO | 0,027 | 0,00 % | NRx Pharmaceuticals, Inc.: GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) | Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the "dark genome" of all people. K Env... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,410 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 16,160 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| IMMUNOVANT | 37,660 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 79,95 | 0,00 % | Jefferies erhöht Kursziel für Tarsus Pharmaceuticals nach Prognoseanhebung | ||
| SUMMIT THERAPEUTICS | 18,420 | 0,00 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| TYRA BIOSCIENCES | 25,070 | 0,00 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,530 | 0,00 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,405 | -0,15 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 24,265 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen |
Das Unternehmen MODUS THERAPEUTICS HOLDING AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,001 (-5,43 %) liegt der Kurs bei 0,024 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MODUS THERAPEUTICS HOLDING AB finden Sie auf Wallstreet Online.